Haisco: Innovative drug HSK47388 tablet approved by FDA for clinical trials.

On July 15th, Hisco announced that the company has recently received a Study May Proceed Letter from the U.S. Food and Drug Administration, approving the clinical trial application for HSK47388 tablet submitted by the company in May 2025. HSK47388 tablet is an orally administered, potent, and highly selective drug developed independently by the company, intended for the treatment of autoimmune diseases. The IND application for this drug has been accepted in China in May 2025 and is currently in the review stage.